Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
Michaela Waibel(St Vincents Institute of Medical Research), Ricky W. Johnstone(Peter MacCallum Cancer Centre)
Cited by 134
Related Papers
New and emerging HDAC inhibitors for cancer treatment
|Journal of Clinical Investigation|2014|1.4k
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
|Cell Reports|2017|297
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments
|Nature|2016|205